scholarly journals Association of C-reactive protein and interleukin-6 with new-onset fatigue in the Whitehall II prospective cohort study

2012 ◽  
Vol 43 (8) ◽  
pp. 1773-1783 ◽  
Author(s):  
H. J. Cho ◽  
M. Kivimäki ◽  
J. E. Bower ◽  
M. R. Irwin
Keyword(s):  
Cohort Study ◽  
Interleukin 6 ◽  
Large Scale ◽  
Short Form ◽  
Low Grade ◽  
Continuous Variables ◽  
C Reactive Protein ◽  
Phase 3 ◽  
Reactive Protein ◽  
New Onset

BackgroundAlthough basic research on neuroimmune interactions suggests that inflammatory processes may play a role in the development of fatigue, population-based evidence on this association is limited. This study examined whether plasma C-reactive protein (CRP) and interleukin-6 (IL-6), biomarkers of systemic inflammation, predict fatigue onset.MethodThe Whitehall II study is a large-scale cohort study conducted in 20 civil service departments in London. Plasma CRP and IL-6 were measured in 4847 non-fatigued participants at phase 3 (1991–1993, aged 39–63 years). Fatigue was assessed using the Vitality subscale of the 36-item Short Form Health Survey (SF-36) at phase 3 and phase 4 (1995–1996).ResultsDuring a mean follow-up of 3.1 years, 957 new fatigue cases (19.7%) were identified using the pre-established cut-off score of ⩽50 on the Vitality subscale. CRP values were dichotomized as low (<1.0 mg/l ) or high (⩾1.0 mg/l) using the Centers for Disease Control/American Heart Association recommendations. Similarly, IL-6 values were also dichotomized as low (<1.5 pg/ml) or high (⩾1.5 pg/ml). After full adjustment for sociodemographic and biobehavioral covariates, the odds ratios for new-onset fatigue were 1.28 [95% confidence interval (CI) 1.09–1.49,p = 0.003] for high CRP and 1.24 (95% CI 1.06–1.45,p = 0.008) for high IL-6. Similar results were found when CRP and IL-6 were treated as continuous variables.ConclusionsPlasma CRP and IL-6 were prospectively associated with new-onset fatigue, supporting the hypothesis that low-grade inflammation has a role in the development of fatigue.

Is there any role of interleukin-6 and high sensitive C-reactive protein in predicting IVF/ICSI success? A prospective cohort study

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
A. Seval Ozgu-Erdinc ◽  
Ilay Gozukara ◽  
Serkan Kahyaoglu ◽  
Saynur Yilmaz ◽  
Omer Hamit Yumusak ◽  
...  
Keyword(s):  
Cohort Study ◽  
Prospective Cohort Study ◽  
Interleukin 6 ◽  
Prospective Cohort ◽  
Clinical Pregnancy ◽  
Low Grade ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Icsi Cycle ◽  
Hs Crp

Abstract Objectives Studies have established a relationship between proinflammatory factors and implantation failure in IVF/ICSI cycles. Likewise, low-grade chronic inflammation is generally blamed for predisposing infertility. In the present study, we aimed to find a relationship between serum IL-6 and hs-CRP levels and IVF/ICSI cycle outcomes. Methods A total of 129 patients who consented to participate and attended the IVF unit of our department for the treatment of infertility have been enrolled in this prospective cohort study. Serum levels of high sensitive C-reactive protein and interleukin 6 have been detected at the beginning of the IVF/ICSI ovulation induction cycle. Cycle outcomes have been compared between patients with and without clinical pregnancy achievement following ART treatments. IVF/ICSI cycle outcomes of these two groups were also comparable except the number of >14 mm follicles, retrieved oocytes, metaphase II oocytes, and fertilized oocytes (2 pronuclei) which were in favor of the clinical pregnancy group. Results Mean serum hs-CRP levels were 3.08 mg/L (0.12–35.04) and 2.28 mg/L (0.09–22.52) patients with and without clinical pregnancy respectively. Mean serum IL-6 levels were 2 pg/mL (1–10.2) and 2 pg/mL (1–76.9) patients with and without clinical pregnancy respectively. Both tests were found to be statistically insignificant in predicting the success of the ART cycle in terms of implantation, clinical pregnancy, miscarriage, and live birth. Conclusions In the present study, we have not found any significant effect of hs-CRP and IL-6 levels in the IVF cycle. However, in the light of this and previous studies, large-scale research may prove the exact influence of these markers on IVF success.

scholarly journals The Use of Liraglutide in Obese Patients With COVID-19: A Case Report

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A38-A39
Author(s):  
Taliê Zanchetta Buani Hanada ◽  
Rafael Silvestre Knack ◽  
Renata Silvestre Knack
Keyword(s):  
Case Report ◽  
General Condition ◽  
Interleukin 6 ◽  
Laboratory Tests ◽  
Low Grade ◽  
Obese Patients ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Good General Condition ◽  
Anti Inflammatory

Abstract Introduction: In December 2019, a new type of coronavirus was discovered in Wuhan, China, characterized by a picture of atypical pneumonia composed of fever, dry cough and progressive dyspnea. Autopsy analyzes of patients with Covid-19 were performed, and hyperactivation of cytotoxic T cells was observed, suggesting an increase in humoral-type immunological signaling, where interleukin 6 (IL-6) is a mediator present that can fit as a potential critical agent for exacerbation of inflammatory conditions. In addition, not only interleukin-6, but also serum C-reactive protein (CRP) and ferritin have been recognized as strong predictors of COVID-19 severity. Recent studies have shown that the use of liraglutide has antioxidant and anti-inflammatory effects in vitro. Thus, the present case report discusses the possible anti-inflammatory properties of the antidiabetic drug liraglutide (Saxenda), in Covid-19. Clinical Case: JCMS, 45 years, male, married, obese grade 2 (BMI: 38.2), sought medical service on August 18, 2020, bringing a positive result of the RT-PCR test for Covid-19, performed in last day. The patient was in good general condition, reporting mild headache and adynamia. He was prescribed to start a treatment with Saxenda (6mg/ml - started 0.6mg/day at week 1, with a gradual increase up to 3mg/day at week 5); Jardiance (25mg / day); Fluimicil (600mg); Ivermectin (6mg) and Colchicine (0.5mg every 12 hours). In addition, collection of laboratory tests was requested. Examination results: IL6: &lt;1.5 pg/mL; Ferritin: 819 ng/ml; C-reactive protein: 5.1mg/L. On August 24, the patient was tachycardic (HR 120–140 bpm) associated with headache and fever (38 °C). Azithromycin (500mg), dexamethasone (4mg) and dipyrone (1g) were prescribed. Collection of laboratory tests was requested. Examination results: IL6: 9.3 pg/mL; Ferritin: 1085 ng/ml; C-reactive protein:23.9mg/L. On September 3, the patient was in good general condition, eupneic, afebrile, with no complaints to declare. On September 6, the collection of laboratory tests was requested. Examination results: IL6: &lt;1.5 pg/mL; Ferritin: 687 ng/ml; C-reactive protein: 1.7mg/L. Conclusion: Based on the described report, it is possible to observe a good clinical and laboratory evolution of the patient with Covid-19 who, among the drugs used, made use of liraglutida. Diabetes and obesity are considered significant risk factors for morbidity and mortality by COVID-19, since they are a condition of low-grade chronic inflammation and in these conditions, inflammatory markers such as CRP, IL-6 and ferritin have strong signs of alteration. Thus, the possible beneficial effect of the administration of liraglutide in obese patients is highlighted, as a potential anti-inflammatory effect, especially in the COVID-19 era.

PSV-B-28 Late-Breaking: Development and validation of a Total Inflammation Index™ for identifying inflammation in Labrador Retrievers using a pressure walkway

2021 ◽  
Vol 99 (Supplement_3) ◽  
pp. 383-384
Author(s):  
Jessica L Varney ◽  
Craig N Coon
Keyword(s):  
Creatine Kinase ◽  
Gait Analysis ◽  
Interleukin 6 ◽  
Cartilage Oligomeric Matrix Protein ◽  
Matrix Protein ◽  
Low Grade ◽  
C Reactive Protein ◽  
Inflammatory Biomarker ◽  
Reactive Protein ◽  
Labrador Retrievers

Abstract The objective of this trial was to develop an index system to identify inflammation in Labrador Retrievers using a pressure walkway system. Gait analysis data can be difficult to interpret between treatment groups or for identifying low grade inflammation. To calculate the Total Inflammation Index™, the distance away from the ideal score was calculated for four parameters for each dog, including gait lameness score, total pressure index, step/stride ratio, and hind reach. These values were equally weighted and added together to produce the Total Inflammation Index™. For validation, the Total Inflammation Index™ values were compared to biomarker data for inflammation including cartilage oligomeric matrix protein, interleukin-6, creatine kinase, and c-reactive protein. Forty Labrador Retrievers (20 male/20 female) were used in this trial. All dogs were passed over the pressure walkway (Gait4Dogs; CIR Systems, Inc) to obtain gait analysis at baseline, 24h prior to the first 5km run, 24h after the first 5km run, 24h prior to the final 16km run, and 24h after the final 16km run. All biomarkers and the Total Inflammation Index™ were both significantly lower at the pre-exercise timepoints and elevated after post-exercise timepoints (P &lt; 0.01). The Total Inflammation Index™ had significant correlation between timepoints and all biomarkers, including cartilage oligomeric matrix protein (P &lt; 0.01), interleukin-6 (P &lt; 0.05), creatine kinase (P &lt; 0.01), and c-reactive protein (P &lt; 0.05). The Total Inflammation Index™ appears to be a valid assay to evaluate generalized inflammation in Labrador Retrievers, and is in agreement with inflammatory biomarker values.

scholarly journals Interleukin-6 and highly sensitive C-reactive protein in obese adolescents

2012 ◽  
Vol 52 (4) ◽  
pp. 219
Author(s):  
Michael Kasenda ◽  
Suryadi Tantura ◽  
Sarah Warouw
Keyword(s):  
Interleukin 6 ◽  
Cross Sectional Study ◽  
Low Grade ◽  
C Reactive Protein ◽  
Tissue Mass ◽  
Cross Sectional ◽  
Obese Adolescents ◽  
Positive Correlation ◽  
Reactive Protein ◽  
Inflammatory State

Background Childhood obesity is a major health concern.Obesity is due to an expansion of adipose tissue mass. This tissueproduces pro􀁞inflarmnatory cytokines, such as interleukin􀁞6 (IL--6).IL􀁞6 is considered to be the chief stimulator of the production ofhighly sensitive C􀁞reactive protein (hsCRP) in the liver. Bothmolecules are responsible for the chronic low􀁞grade inflammatorystate in obese individuals.Objective To assess a correlation between IL􀁞6 and hsCRP inobese adolescents.Methods This cross􀁞sectional study was conducted from Marchto June 2011 in Manado. Subjects were obese and normal bodymass index (BMI) teens aged 13􀁞18 years. Serum glutamicoxaloacetic transaminase (SOOT) and serum glutamic pyruvictransaminase (SOPT) levels were measured to rule out liverimpairment. IL􀁞6 and hsCRP levels were also measured. Data wasanalyzed by Pearson's correlation and linear regression to test forcorrelation between IL--6 and hsCRP levels.Results There was a strongly positive correlation between IL􀁞6and hsCRP levels in obese adolescents (r=0.79 with P<O.OOl).IL--6 and hsCRP levels were not significantly associated in subjectswith normal BMI.Conclusions There was a strongly positive correlation betweenIL--6 and hsCRP levels in obese adolescents, suggestive of anongoing, chronic, low􀁞grade inflammatory state. [PaediatrIndanes.2012;52:219-22].

scholarly journals The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study

2019 ◽  
Vol 40 (48) ◽  
pp. 3901-3909 ◽  
Author(s):  
Cilie C van’t Klooster ◽  
Paul M Ridker ◽  
Jesper Hjortnaes ◽  
Yolanda van der Graaf ◽  
Folkert W Asselbergs ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cardiovascular Disease ◽  
Cohort Study ◽  
Low Grade ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Incident Cancer ◽  
Risk Of Cancer ◽  
Low Grade Inflammation

Abstract Aims Low-grade inflammation, measured by elevated plasma concentrations of high-sensitive C-reactive protein (CRP), is a risk factor for cardiovascular disease (CVD). There is evidence that low-grade inflammation is also related to a higher risk of cancer. The present prospective cohort study evaluates the relation between low-grade systemic inflammation and risk of cancer in patients with stable CVD. Methods and results In total, 7178 patients with stable CVD and plasma CRP levels ≤10 mg/L were included. Data were linked to the Dutch national cancer registry. Cox regression models were fitted to study the relation between CRP and incident CVD and cancer. After a median follow-up time of 8.3 years (interquartile range 4.6–12.3) 1072 incident cancer diagnoses were observed. C-reactive protein concentration was related to total cancer [hazard ratio (HR) 1.35; 95% confidence interval (CI) 1.10–1.65] comparing last quintile to first quintile of CRP. Especially lung cancer, independent of histopathological subtype, was related to CRP (HR 3.39; 95% CI 2.02–5.69 comparing last to first quintile of CRP). Incidence of epithelial neoplasms and especially squamous cell neoplasms were related to CRP concentration, irrespective of anatomical location. Sensitivity analyses after excluding patients with a cancer diagnosis within 1, 2, and 5 years of follow-up showed similar results. No effect modification was observed by smoking status or time since smoking cessation (P-values for interaction &gt; 0.05). Conclusion Chronic systemic low-grade inflammation, measured by CRP levels ≤10 mg/L, is a risk factor for incident cancer, markedly lung cancer, in patients with stable CVD. The relation between inflammation and incident cancer is seen in former and current smokers and is uncertain in never smokers.

Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease

2021 ◽  
Author(s):  
Paul M Ridker ◽  
Manas Rane
Keyword(s):  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Interleukin 6 ◽  
Large Scale ◽  
Immune Cell ◽  
Interleukin 1 ◽  
C Reactive Protein ◽  
Vascular Protection ◽  
Reactive Protein

Interleukin-6 (IL-6) is a pivotal cytokine of innate immunity which enacts a broad set of physiologic functions traditionally associated with host defense, immune cell regulation, proliferation, and differentiation. Following recognition of innate immune pathways leading from the NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome to interleukin-1 to IL-6 and on to the hepatically derived clinical biomarker C-reactive protein, an expanding literature has led to understanding of the pro-atherogenic role for IL-6 in cardiovascular disease and thus the potential for interleukin-6 inhibition as a novel method for vascular protection. In this review, we provide an overview of the mechanisms by which IL-6 signaling occurs and how that impacts upon pharmacologic inhibition; describe murine models of IL-6 and atherogenesis; summarize human epidemiologic data outlining the utility of IL-6 as a biomarker of vascular risk; outline genetic data suggesting a causal role for IL-6 in systemic atherothrombosis and aneurysm formation; and then detail the potential role of IL-6 inhibition in stable coronary disease, acute coronary syndromes, heart failure, and the atherothrombotic complications associated with chronic kidney disease and end-stage renal failure. Finally, we review anti-inflammatory and anti-thrombotic findings for ziltivekimab, a novel IL-6 ligand inhibitor being developed specifically for use in atherosclerotic disease and poised to be tested formally in a large scale cardiovascular outcomes trial focused on individuals with chronic kidney disease and elevated levels of C-reactive protein, a population at high residual atherothrombotic risk, high residual inflammatory risk, and considerable unmet clinical need.

Sign in / Sign up

Export Citation Format

Share Document